contiguous stage II mantle cell lymphoma
Showing 1 - 25 of >10,000
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in
Completed
- Contiguous Stage II Mantle Cell Lymphoma
- +5 more
- bortezomib
- +9 more
-
Duarte, California
- +1 more
Jan 12, 2022
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +71 more
- lenalidomide
- +8 more
-
Chicago, Illinois
- +5 more
Oct 8, 2021
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma Trial in
Active, not recruiting
- Contiguous Stage II Mantle Cell Lymphoma
- +4 more
- ibrutinib
- laboratory biomarker analysis
-
Chicago, Illinois
- +4 more
Apr 30, 2021
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Terminated
- Adult Grade III Lymphomatoid Granulomatosis
- +116 more
- brentuximab vedotin
- +2 more
-
Chicago, Illinois
- +2 more
Aug 30, 2021
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma
Completed
- Adult Grade III Lymphomatoid Granulomatosis
- +88 more
- bortezomib
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Apr 14, 2021
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma Trial in
Active, not recruiting
- Stage I Mantle Cell Lymphoma
- +4 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Buffalo, New York
- +1 more
Mar 9, 2022
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Completed
- Hematopoietic/Lymphoid Cancer
- +135 more
- beclomethasone dipropionate
- +4 more
-
Hackensack, New Jersey
- +1 more
Feb 1, 2021
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)
Not yet recruiting
- Mantle-cell Lymphoma
- Polatuzumab, bendamustin und rituximab
- (no location specified)
May 11, 2023
Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma
- (no location specified)
Oct 31, 2022
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
-
Washington, District of Columbia
- +6 more
Feb 2, 2023
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Low Dose Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Mantle Cell Lymphoma Trial in United States (R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.)
Active, not recruiting
- Mantle Cell Lymphoma
- R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
-
Basking Ridge, New Jersey
- +4 more
Dec 1, 2022
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- +6 more
-
Beijing, ChinaBeijing Cancer Hospital
Feb 6, 2023
Mantle Cell Lymphoma Recurrent Trial in Melbourne (ibrutinib and Tisagenlecleucel)
Active, not recruiting
- Mantle Cell Lymphoma Recurrent
- ibrutinib and Tisagenlecleucel
-
Melbourne, Victoria, AustraliaPeter Mac Callum Cancer Centre
Nov 4, 2022
Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)
Recruiting
- Mantle Cell Lymphoma
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)
Active, not recruiting
- CCND1 Positive
- +2 more
- Bendamustine
- +2 more
-
Atlanta, Georgia
- +2 more
Nov 2, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)
Not yet recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Biopsy
- +10 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 9, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Mantle Cell Lymphoma Trial in Baltimore (Venetoclax Oral Tablet [Venclexta])
Recruiting
- Mantle Cell Lymphoma
- Venetoclax Oral Tablet [Venclexta]
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jun 29, 2022